An anti-GD2 antibody is a monoclonal antibody that specifically binds to the GD2 antigen. By targeting GD2, these antibodies can mark cancer cells for destruction by the immune system. Examples of anti-GD2 antibodies include dinutuximab and naxitamab, which are used in the treatment of high-risk neuroblastoma.
